![]() "It's a small data set, but the evidence is there." The case of Jace Ward The findings are a hopeful sign for many types of brain tumors, not just this one, she added. ![]() "We see significant anti-tumor activity with these CAR-T cell therapies in this dreaded disease," said cancer immunotherapy expert Crystal Mackall, MD, who shares senior authorship of the new research with Monje. The FDA approved the use of engineered immune cells, also known as chimeric antigen receptor T-cells, or CAR-T cells, to treat blood cancers in 2017, but the technology has not previously succeeded against solid tumors.Īlthough the research team has yet to achieve a cure for this type of glioma, they consider their findings a milestone. "They taught us so much, and that knowledge is already being applied to help other kids." "These four patients are heroes," said study's principal investigator, pediatric neuro-oncologist Michelle Monje, MD, PhD. Though all the trial patients died of their disease or its complications, three of them experienced significant clinical benefits from the engineered cells. He was one of the first four patients with diffuse intrinsic pontine glioma or a closely related cancer affecting the spinal cord to receive immune cells engineered to fight the disease. Today a group of Stanford scientists who have spent the past decade unlocking the glioma's secrets are publishing data in Naturefrom the trial Ward joined. ![]() The disease has a five-year survival rate of less than one percent. His diagnosis was diffuse intrinsic pontine glioma, or DIPG, which conventional cancer treatments can't cure. When Jace Ward came to Lucile Packard Children's Hospital Stanford in September 2020 to join a clinical trial for a novel therapy, he had been fighting a deadly brainstem tumor for more than a year.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |